#ASGCT26: After an apparent cure, a gene editing company struggles to repeat the magic

Jim Wilson, iECURE scientific advisor (Credit: GEMMABio) May 13, 2026 02:50 PM EDT StartupsR&DCell/Gene Tx Af­ter an ap­par­ent cure, a gene edit­ing com­pa­ny strug­gles to re­peat the mag­ic Ryan Cross Senior Science Correspondent BOSTON — Ear­ly last year, start­up iECURE’s ex­per­i­men­tal gene ther­a­py seem­ing­ly cured a ba­by of a life-threat­en­ing ge­net­ic dis­ease. But new re­sults test­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER